Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Pancreatitis Male or female patients between the ages of 18 and 75 years with a diagnosis of chronic pancreatitis diagnosed using the Mayo Clinic Diagnostic ((Layer P, Gastroenterology 1994;107:1481-1487]). Both diabetic and non-diabetic patients will be allowed to enter the study. 2. The patients must suffer from chronic abdominal pain typical for pancreatitis, meet the for chronic pain (pain ≥ 3 days per week in at least 3 months) and must consider their pain as severe enough for medical treatment. 3. Personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial. 4. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other trial procedures  Patients with evidence or history of medical or surgical disease of importance for this study as judged by investigator 2. Presence or history of major depression 3. Patients with previously diagnosed moderate to severe renal impairment. Patients with creatinine values > 2x ULN and/or with a significant change to their normal values should be excluded. 4. Patients with a screening 12-lead ECG demonstrating any of the following: heart rate >100 bpm, QRS duration >120 msec, QTc interval >450 msec, PR interval >210 msec, any clinically significant rhythm abnormality, any evidence of myocardial ischemia or injury. 5. Patients with any clinically significant laboratory abnormalities that in the opinion of the investigator may increase the risk associated with trial participation or may interfere with the interpretation of the trial results. 6. Patients treated with pregabalin (Lyrica®) during the previous 4 months. 7. Treatment with an investigational drug within 4 months preceding the first dose of study medication of importance for this study as judged by investigator. 8. Female patients who are pregnant or lactating, or intend to become pregnant. Male patients who intend to father a child during the course of the study. A pregnancy test will be conducted at visit 1 and 3 to ensure that female patients are not pregnant during the study period. The investigator will have to ensure that fertile female patients use a safe contraception method during the study and for at least 35 hours after termination of the study period. The following methods are considered as safe contraception methods The pill IUD Gestagen Injection Subdermal Implantation (Implanon) Hormone vaginal ring Transdermal Plaster 9. Patients unwilling or unable to comply with the lifestyle guidelines. 10. Patients must not suffer from generalized painful conditions other than chronic pancreatitis; however patients with localized painful disorders will be allowed to enter the study 11. Clinical significant illness within two weeks of participating in this study. 12. Involved in planning or conducting the study. 13. Hypersensitivity to pregabalin or any of its components